HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
Summary
A summary of the main changes and business highlights during Q1 FY2025 include: HeartSciences is uniquely developing both cloud and device-based AI-ECG solutions, driving innovation in heart disease detection. This versatility will enable AI-ECG solutions to be provided across a wide range of healthcare settings, from large hospital systems to simple nurse-led mobile testing services. HeartSciences selected to demonstrate MyoVista\xae wavECG at the United Nations General Assembly Digital Health Symposium at the end of September, as a technology to radically transform healthcare. This follows continued expansion of our key opinion leader network outside the U.S. and the reception of strong feedback from real world clinical use of a small number of MyoVista\xae wavECG devices which were placed in Europe. We are laying the long-term foundations to solve the diagnostic gap for the early detection of heart disease, which represents one of the most significant benefits for healthcare worldwide, said Andrew Simpson, CEO of HeartSciences.Our team remains focused on getting through regulatory submission for the MyoVista\xae wavECG as quickly as practical, and we continue to work methodically and diligently to bring a successful conclusion to many years and several tens of millions of dollars of investment in R&D, clinical studies and regulatory work.Feedback on our MyoVista Insights platform has been positive and work to bring forward the first of the Mount Sinai licensed algorithms is well underway.